{
    "info": {
        "nct_id": "NCT03871257",
        "official_title": "A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)",
        "inclusion_criteria": "* Patients must be >= 2 years and =< 21 years at the time of enrollment\n* Patients must have a body surface area (BSA) of >= 0.5 m^2 at enrollment\n* Patients must have neurofibromatosis type 1 (NF1) based on clinical criteria and/or germline genetic testing\n* Patients must be newly diagnosed or have previously diagnosed NF-1 associated LGG that has not been treated with any modality other than surgery\n* For patients with optic pathway gliomas (OPGs):\n\n  * Newly-diagnosed patients with OPG are eligible if there are neurologic symptoms (including visual dysfunction, as defined below) or other exam findings associated with the tumor\n  * Previously-diagnosed patients with OPG are eligible if they have new or worsening neurologic symptoms (including visual dysfunction, as defined below) or have tumor growth\n  * For both newly-diagnosed and previously-diagnosed OPG, the patient may be eligible, irrespective of whether there has been tumor growth or other neurological symptoms or worsening, if they meet at least one of the following visual criteria:\n\n    * Visual worsening, defined as worsening of visual acuity (VA) or visual fields (VF) documented within the past year (by examination or history); OR\n    * Significant visual dysfunction (defined as VA worse than normal for age by 0.6 logMAR [20/80, 6/24, or 2.5/10] or more in one or both eyes)\n* For patients with LGG in other locations (i.e., not OPGs):\n\n  * Newly-diagnosed patients with LGG are eligible if there are neurologic symptoms or other exam findings associated with the tumor\n\n    * NOTE: Newly-diagnosed patients with LGG without associated neurologic symptoms or exam findings are not eligible\n  * Previously-diagnosed patients with LGG are eligible if they have new or worsening neurologic symptoms or have tumor growth\n* Although not required, if a biopsy/tumor resection is performed, eligible histologies will include all tumors considered LGG or low-grade astrocytoma (World Health Organization [WHO] grade I and II) by 5th edition WHO classification of central nervous system (CNS) tumors with the exception of subependymal giant cell astrocytoma\n* Patients must have two-dimensional measurable tumor >= 1 cm^2\n* Patients with metastatic disease or multiple independent primary LGGs are allowed on study\n* Creatinine clearance or radioisotope glomerular filtration Rate (GFR) >= 70 mL/min/1.73 m^2 OR a serum creatinine based on age/sex (within 7 days prior to enrollment) as follows:\n\n  * Age; maximum serum creatinine (mg/dL)\n  * 2 to < 6 years; 0.8 (male) and 0.8 (female)\n  * 6 to < 10 years; 1 (male) and 1 (female)\n  * 10 to < 13 years; 1.2 (male) and 1.2 (female)\n  * 13 to < 16 years; 1.5 (male) and 1.4 (female)\n  * >= 16 years; 1.7 (male) and 1.4 (female)\n* Total bilirubin =< 1.5 x upper limit of normal (ULN) for age (within 7 days prior to enrollment) (children with a diagnosis of Gilbert's syndrome will be allowed on study regardless of their total and indirect [unconjugated] bilirubin levels as long as their direct [conjugated] bilirubin is < 3.1 mg/dL)\n* Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 3 x upper limit of normal (ULN) = 135 U/L (within 7 days prior to enrollment). For the purpose of this study, the ULN for SGPT is 45 U/L\n* Albumin >= 2 g/dL (within 7 days prior to enrollment)\n* Left ventricular ejection fraction (LVEF) >= 53% (or institutional normal; if the LVEF result is given as a range of values, then the upper value of the range will be used) by echocardiogram (within 4 weeks prior to enrollment)\n* Corrected QT (QTc) interval =< 450 msec by electrocardiography (EKG) (within 4 weeks prior to enrollment)\n* Absolute neutrophil count >= 1,000/uL (unsupported) (within 7 days prior to enrollment)\n* Platelets >= 100,000/uL (unsupported) (within 7 days prior to enrollment)\n* Hemoglobin >= 8 g/dL (may be supported) (within 7 days prior to enrollment)\n* Patients with a known seizure disorder should be stable and should have not experienced a significant increase in seizure frequency within 2 weeks prior to enrollment\n* Patients 2-17 years of age must have a blood pressure that is =< 95th percentile for age, height, and sex at the time of enrollment. Patients >= 18 years of age must have a blood pressure =< 130/80 mmHg at the time of enrollment (with or without the use of antihypertensive medications).\n\n  * Note: Adequate blood pressure can be achieved using medication for the treatment of hypertension\n* All patients must have ophthalmology toxicity assessments performed within 8 weeks prior to enrollment\n* For all patients, an MRI of the brain (with orbital cuts for optic pathway tumors) and/or spine (depending on the site(s) of primary disease) with and without contrast must be performed within 8 weeks prior to enrollment\n* For patients who undergo a surgery on the target tumor (not required), a pre- and post-operative* MRI of the brain (with orbital cuts for optic pathway tumors) or spine (depending on the site(s) of primary disease) with and without contrast must also be performed. The post-operative MRI must be performed within 4 weeks prior to enrollment. If only a biopsy is performed, a post-operative MRI is not required and the pre-operative (op) MRI within 8 weeks of enrollment will be used as the baseline scan\n\n  * The post-operative MRIs should be performed ideally within 48 hours after surgery if possible\n* Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, or 2. Use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age\n* Patients must have the ability to swallow whole capsules\n* Patients must have receptive and expressive language skills in English, Spanish or French to complete the quality of life (QOL) and neurocognitive assessments\n* All patients and/or their parents or legal guardians must sign a written informed consent.\n* All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met.\nHealthy volunteers allowed\nMust have minimum age of 2 Years\nMust have maximum age of 21 Years",
        "exclusion_criteria": "* Patients must not have received any prior tumor-directed therapy including chemotherapy, radiation therapy, immunotherapy, or bone marrow transplant. Prior surgical intervention is permitted\n* Patients with a concurrent malignancy or history of treatment (other than surgery) for another tumor within the last year are ineligible\n* Patients may not be receiving any other investigational agents\n* Patients with any serious medical or psychiatric illness/ condition, including substance use disorders likely in the judgement of the investigator to interfere or limit compliance with study requirements/treatment are not eligible\n* Patients who, in the opinion of the investigator, are not able to comply with the study procedures are not eligible\n* Female patients who are pregnant are not eligible since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential\n* Lactating females who plan to breastfeed their infants are not eligible\n* Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation and for 12 weeks after stopping study therapy are not eligible\n\n  * Note: Women of child-bearing potential and males with sexual partners who are pregnant or who could become pregnant (i.e., women of child-bearing potential) should use effective methods of contraception for the duration of the study and for 12 weeks after stopping study therapy to avoid pregnancy and/or potential adverse effects on the developing embryo\n* Cardiac conditions:\n\n  * Known genetic disorder that increases risk for coronary artery disease. Note: The presence of dyslipidemia in a family with a history of myocardial infarction is not in itself an exclusion unless there is a known genetic disorder documented\n  * Symptomatic heart failure\n  * New York Heart Association (NYHA) class II-IV prior or current cardiomyopathy\n  * Severe valvular heart disease\n  * History of atrial fibrillation\n* Ophthalmologic conditions:\n\n  * Current or past history of central serous retinopathy\n  * Current or past history of retinal vein occlusion or retinal detachment\n  * Patients with uncontrolled glaucoma\n\n    * If checking pressure is clinically indicated, patients with intraocular pressure (IOP) > 22 mmHg or ULN adjusted by age are not eligible\n  * Ophthalmological findings secondary to long-standing optic pathway glioma (such as visual loss, optic nerve pallor, or strabismus) or longstanding orbito-temporal plexiform neurofibroma (PN), such as visual loss, strabismus) will NOT be considered a significant abnormality for the purposes of the study\n* Treatments and/or medications patient is receiving that would make her/him ineligible, such as:\n\n  * Supplementation with vitamin E greater than 100% of the daily recommended dose. Any multivitamin containing vitamin E must be stopped prior to study enrollment even if less than 100% of the daily recommended dosing for vitamin E\n  * Surgery within 2 weeks prior to enrollment, with the exception of surgical placement for vascular access or cerebrospinal fluid (CSF) diverting procedures such as endoscopic third ventriculostomy (ETV) and ventriculo-peritoneal (VP) shunt.\n\n    * Note: Patients must have healed from any prior surgery prior to enrollment\n* Patients who have an uncontrolled infection are not eligible",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Previously-diagnosed patients with OPG are eligible if they have new or worsening neurologic symptoms (including visual dysfunction, as defined below) or have tumor growth",
            "criterions": [
                {
                    "exact_snippets": "Previously-diagnosed patients with OPG",
                    "criterion": "optic pathway glioma (OPG) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "history of diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "new or worsening neurologic symptoms (including visual dysfunction, as defined below)",
                    "criterion": "neurologic symptoms",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "new",
                                "worsening"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "visual dysfunction, as defined below",
                    "criterion": "visual dysfunction",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "new",
                                "worsening"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "tumor growth",
                    "criterion": "tumor growth",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Albumin >= 2 g/dL (within 7 days prior to enrollment)",
            "criterions": [
                {
                    "exact_snippets": "Albumin >= 2 g/dL",
                    "criterion": "albumin level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met.",
            "criterions": [
                {
                    "exact_snippets": "All institutional ... requirements for human studies must be met.",
                    "criterion": "institutional requirements for human studies",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Food and Drug Administration (FDA) ... requirements for human studies must be met.",
                    "criterion": "FDA requirements for human studies",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "National Cancer Institute (NCI) requirements for human studies must be met.",
                    "criterion": "NCI requirements for human studies",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For both newly-diagnosed and previously-diagnosed OPG, the patient may be eligible, irrespective of whether there has been tumor growth or other neurological symptoms or worsening, if they meet at least one of the following visual criteria:",
            "criterions": [
                {
                    "exact_snippets": "newly-diagnosed ... OPG",
                    "criterion": "OPG diagnosis status",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis status",
                            "expected_value": "newly-diagnosed"
                        }
                    ]
                },
                {
                    "exact_snippets": "previously-diagnosed OPG",
                    "criterion": "OPG diagnosis status",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis status",
                            "expected_value": "previously-diagnosed"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 3 x upper limit of normal (ULN) = 135 U/L (within 7 days prior to enrollment). For the purpose of this study, the ULN for SGPT is 45 U/L",
            "criterions": [
                {
                    "exact_snippets": "Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 3 x upper limit of normal (ULN) = 135 U/L (within 7 days prior to enrollment). For the purpose of this study, the ULN for SGPT is 45 U/L",
                    "criterion": "serum glutamate pyruvate transaminase (SGPT) / alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 135,
                                "unit": "U/L"
                            }
                        },
                        {
                            "requirement_type": "measurement_timeframe",
                            "expected_value": "within 7 days prior to enrollment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Creatinine clearance or radioisotope glomerular filtration Rate (GFR) >= 70 mL/min/1.73 m^2 OR a serum creatinine based on age/sex (within 7 days prior to enrollment) as follows:",
            "criterions": [
                {
                    "exact_snippets": "Creatinine clearance ... >= 70 mL/min/1.73 m^2",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 70,
                                "unit": "mL/min/1.73 m^2"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "radioisotope glomerular filtration Rate (GFR) >= 70 mL/min/1.73 m^2",
                    "criterion": "glomerular filtration rate (GFR) by radioisotope",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 70,
                                "unit": "mL/min/1.73 m^2"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "serum creatinine based on age/sex (within 7 days prior to enrollment)",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": "based on age/sex-specific reference range"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 7 days prior to enrollment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Newly-diagnosed patients with OPG are eligible if there are neurologic symptoms (including visual dysfunction, as defined below) or other exam findings associated with the tumor",
            "criterions": [
                {
                    "exact_snippets": "Newly-diagnosed patients with OPG",
                    "criterion": "optic pathway glioma (OPG) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis status",
                            "expected_value": "newly-diagnosed"
                        }
                    ]
                },
                {
                    "exact_snippets": "neurologic symptoms (including visual dysfunction, as defined below)",
                    "criterion": "neurologic symptoms",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "visual dysfunction, as defined below",
                    "criterion": "visual dysfunction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "other exam findings associated with the tumor",
                    "criterion": "other exam findings associated with the tumor",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have the ability to swallow whole capsules",
            "criterions": [
                {
                    "exact_snippets": "ability to swallow whole capsules",
                    "criterion": "ability to swallow whole capsules",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Newly-diagnosed patients with LGG are eligible if there are neurologic symptoms or other exam findings associated with the tumor",
            "criterions": [
                {
                    "exact_snippets": "Newly-diagnosed patients with LGG",
                    "criterion": "diagnosis of low-grade glioma (LGG)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis status",
                            "expected_value": "newly-diagnosed"
                        }
                    ]
                },
                {
                    "exact_snippets": "neurologic symptoms ... associated with the tumor",
                    "criterion": "neurologic symptoms associated with the tumor",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "other exam findings associated with the tumor",
                    "criterion": "other exam findings associated with the tumor",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* >= 16 years; 1.7 (male) and 1.4 (female)",
            "criterions": [
                {
                    "exact_snippets": ">= 16 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 16,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "1.7 (male) and 1.4 (female)",
                    "criterion": "body surface area",
                    "requirements": [
                        {
                            "requirement_type": "minimum body surface area (male)",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.7,
                                "unit": "m^2"
                            }
                        },
                        {
                            "requirement_type": "minimum body surface area (female)",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.4,
                                "unit": "m^2"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Visual worsening, defined as worsening of visual acuity (VA) or visual fields (VF) documented within the past year (by examination or history); OR",
            "criterions": [
                {
                    "exact_snippets": "Visual worsening, defined as worsening of visual acuity (VA) or visual fields (VF) documented within the past year (by examination or history)",
                    "criterion": "visual worsening",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "within the past year"
                        }
                    ]
                },
                {
                    "exact_snippets": "worsening of visual acuity (VA)",
                    "criterion": "visual acuity",
                    "requirements": [
                        {
                            "requirement_type": "change",
                            "expected_value": "worsening"
                        }
                    ]
                },
                {
                    "exact_snippets": "worsening of ... visual fields (VF)",
                    "criterion": "visual fields",
                    "requirements": [
                        {
                            "requirement_type": "change",
                            "expected_value": "worsening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For patients who undergo a surgery on the target tumor (not required), a pre- and post-operative* MRI of the brain (with orbital cuts for optic pathway tumors) or spine (depending on the site(s) of primary disease) with and without contrast must also be performed. The post-operative MRI must be performed within 4 weeks prior to enrollment. If only a biopsy is performed, a post-operative MRI is not required and the pre-operative (op) MRI within 8 weeks of enrollment will be used as the baseline scan",
            "criterions": [
                {
                    "exact_snippets": "patients who undergo a surgery on the target tumor (not required)",
                    "criterion": "surgery on target tumor",
                    "requirements": [
                        {
                            "requirement_type": "history of surgery",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "pre- and post-operative* MRI of the brain (with orbital cuts for optic pathway tumors) or spine (depending on the site(s) of primary disease) with and without contrast must also be performed",
                    "criterion": "MRI imaging (pre- and post-operative)",
                    "requirements": [
                        {
                            "requirement_type": "modality",
                            "expected_value": [
                                "brain MRI",
                                "spine MRI"
                            ]
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "pre-operative",
                                "post-operative"
                            ]
                        },
                        {
                            "requirement_type": "contrast",
                            "expected_value": [
                                "with contrast",
                                "without contrast"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "The post-operative MRI must be performed within 4 weeks prior to enrollment",
                    "criterion": "post-operative MRI timing",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to enrollment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "If only a biopsy is performed, a post-operative MRI is not required and the pre-operative (op) MRI within 8 weeks of enrollment will be used as the baseline scan",
                    "criterion": "pre-operative MRI timing (biopsy only)",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 8,
                                "unit": "weeks prior to enrollment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must be newly diagnosed or have previously diagnosed NF-1 associated LGG that has not been treated with any modality other than surgery",
            "criterions": [
                {
                    "exact_snippets": "newly diagnosed or have previously diagnosed NF-1 associated LGG",
                    "criterion": "NF-1 associated low-grade glioma (LGG) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis status",
                            "expected_value": [
                                "newly diagnosed",
                                "previously diagnosed"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "not been treated with any modality other than surgery",
                    "criterion": "prior treatment for NF-1 associated LGG",
                    "requirements": [
                        {
                            "requirement_type": "treatment history",
                            "expected_value": "surgery only"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Left ventricular ejection fraction (LVEF) >= 53% (or institutional normal; if the LVEF result is given as a range of values, then the upper value of the range will be used) by echocardiogram (within 4 weeks prior to enrollment)",
            "criterions": [
                {
                    "exact_snippets": "Left ventricular ejection fraction (LVEF) >= 53% (or institutional normal; if the LVEF result is given as a range of values, then the upper value of the range will be used) by echocardiogram (within 4 weeks prior to enrollment)",
                    "criterion": "left ventricular ejection fraction (LVEF)",
                    "requirements": [
                        {
                            "requirement_type": "measurement method",
                            "expected_value": "echocardiogram"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 4 weeks prior to enrollment"
                        },
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 53,
                                        "unit": "%"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "alternative value",
                            "expected_value": "institutional normal"
                        },
                        {
                            "requirement_type": "range reporting",
                            "expected_value": "if the LVEF result is given as a range of values, then the upper value of the range will be used"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, or 2. Use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age",
            "criterions": [
                {
                    "exact_snippets": "performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, or 2",
                    "criterion": "performance status (ECOG)",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": [
                                "0",
                                "1",
                                "2"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Use Karnofsky for patients > 16 years of age",
                    "criterion": "performance status (Karnofsky)",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">",
                                "value": 16,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "scale",
                            "expected_value": "Karnofsky"
                        }
                    ]
                },
                {
                    "exact_snippets": "Lansky for patients =< 16 years of age",
                    "criterion": "performance status (Lansky)",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": "<=",
                                "value": 16,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "scale",
                            "expected_value": "Lansky"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For patients with optic pathway gliomas (OPGs):",
            "criterions": [
                {
                    "exact_snippets": "optic pathway gliomas (OPGs)",
                    "criterion": "optic pathway glioma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* All patients and/or their parents or legal guardians must sign a written informed consent.",
            "criterions": [
                {
                    "exact_snippets": "All patients and/or their parents or legal guardians must sign a written informed consent.",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For patients with LGG in other locations (i.e., not OPGs):",
            "criterions": [
                {
                    "exact_snippets": "patients with LGG in other locations (i.e., not OPGs)",
                    "criterion": "low-grade glioma (LGG) location",
                    "requirements": [
                        {
                            "requirement_type": "location",
                            "expected_value": "not optic pathway gliomas (OPGs)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NOTE: Newly-diagnosed patients with LGG without associated neurologic symptoms or exam findings are not eligible",
            "criterions": [
                {
                    "exact_snippets": "Newly-diagnosed patients with LGG",
                    "criterion": "diagnosis of low-grade glioma (LGG)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis status",
                            "expected_value": "newly-diagnosed"
                        },
                        {
                            "requirement_type": "disease type",
                            "expected_value": "low-grade glioma (LGG)"
                        }
                    ]
                },
                {
                    "exact_snippets": "without associated neurologic symptoms or exam findings are not eligible",
                    "criterion": "neurologic symptoms or exam findings",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Previously-diagnosed patients with LGG are eligible if they have new or worsening neurologic symptoms or have tumor growth",
            "criterions": [
                {
                    "exact_snippets": "Previously-diagnosed patients with LGG",
                    "criterion": "low-grade glioma (LGG) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "history of diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "new or worsening neurologic symptoms",
                    "criterion": "neurologic symptoms",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "new",
                                "worsening"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "tumor growth",
                    "criterion": "tumor growth",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* 6 to < 10 years; 1 (male) and 1 (female)",
            "criterions": [
                {
                    "exact_snippets": "6 to < 10 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 6,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<",
                                        "value": 10,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "1 (male)",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "male"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "1 (female)",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "female"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have two-dimensional measurable tumor >= 1 cm^2",
            "criterions": [
                {
                    "exact_snippets": "two-dimensional measurable tumor >= 1 cm^2",
                    "criterion": "tumor",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "cm^2"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* 13 to < 16 years; 1.5 (male) and 1.4 (female)",
            "criterions": [
                {
                    "exact_snippets": "13 to < 16 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 13,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<",
                                        "value": 16,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "1.5 (male) and 1.4 (female)",
                    "criterion": "minimum value (sex-specific)",
                    "requirements": [
                        {
                            "requirement_type": "minimum value (male)",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "N/A"
                            }
                        },
                        {
                            "requirement_type": "minimum value (female)",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.4,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The post-operative MRIs should be performed ideally within 48 hours after surgery if possible",
            "criterions": [
                {
                    "exact_snippets": "post-operative MRIs should be performed",
                    "criterion": "post-operative MRI",
                    "requirements": [
                        {
                            "requirement_type": "performance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ideally within 48 hours after surgery",
                    "criterion": "post-operative MRI timing",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 48,
                                "unit": "hours after surgery"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* 2 to < 6 years; 0.8 (male) and 0.8 (female)",
            "criterions": [
                {
                    "exact_snippets": "2 to < 6 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<",
                                        "value": 6,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "0.8 (male) and 0.8 (female)",
                    "criterion": "unknown parameter (likely a lab value or ratio)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": [
                                "0.8 (male)",
                                "0.8 (female)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin >= 8 g/dL (may be supported) (within 7 days prior to enrollment)",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin >= 8 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 21 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 21 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 21,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must be >= 2 years and =< 21 years at the time of enrollment",
            "criterions": [
                {
                    "exact_snippets": "Patients must be >= 2 years and =< 21 years at the time of enrollment",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age at enrollment",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 21,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Significant visual dysfunction (defined as VA worse than normal for age by 0.6 logMAR [20/80, 6/24, or 2.5/10] or more in one or both eyes)",
            "criterions": [
                {
                    "exact_snippets": "Significant visual dysfunction (defined as VA worse than normal for age by 0.6 logMAR [20/80, 6/24, or 2.5/10] or more in one or both eyes)",
                    "criterion": "visual acuity",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.6,
                                "unit": "logMAR"
                            }
                        },
                        {
                            "requirement_type": "comparison to normal for age",
                            "expected_value": "worse than normal for age"
                        },
                        {
                            "requirement_type": "laterality",
                            "expected_value": [
                                "one eye",
                                "both eyes"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* 10 to < 13 years; 1.2 (male) and 1.2 (female)",
            "criterions": [
                {
                    "exact_snippets": "10 to < 13 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 10,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<",
                                        "value": 13,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "1.2 (male) and 1.2 (female)",
                    "criterion": "some measurement (unspecified) for both male and female",
                    "requirements": [
                        {
                            "requirement_type": "value (male)",
                            "expected_value": {
                                "operator": "=",
                                "value": 1.2,
                                "unit": "N/A"
                            }
                        },
                        {
                            "requirement_type": "value (female)",
                            "expected_value": {
                                "operator": "=",
                                "value": 1.2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have receptive and expressive language skills in English, Spanish or French to complete the quality of life (QOL) and neurocognitive assessments",
            "criterions": [
                {
                    "exact_snippets": "Patients must have receptive and expressive language skills in English, Spanish or French",
                    "criterion": "receptive and expressive language skills",
                    "requirements": [
                        {
                            "requirement_type": "language",
                            "expected_value": [
                                "English",
                                "Spanish",
                                "French"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "to complete the quality of life (QOL) and neurocognitive assessments",
                    "criterion": "ability to complete quality of life (QOL) and neurocognitive assessments",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age; maximum serum creatinine (mg/dL)",
            "criterions": [
                {
                    "exact_snippets": "Age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "specified elsewhere (not in this line)"
                        }
                    ]
                },
                {
                    "exact_snippets": "maximum serum creatinine (mg/dL)",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "maximum value",
                            "expected_value": "specified elsewhere (not in this line)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 2 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 2 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Note: Adequate blood pressure can be achieved using medication for the treatment of hypertension",
            "criterions": [
                {
                    "exact_snippets": "Adequate blood pressure can be achieved using medication for the treatment of hypertension",
                    "criterion": "blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment method",
                            "expected_value": "using medication for the treatment of hypertension"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with a known seizure disorder should be stable and should have not experienced a significant increase in seizure frequency within 2 weeks prior to enrollment",
            "criterions": [
                {
                    "exact_snippets": "Patients with a known seizure disorder",
                    "criterion": "seizure disorder",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "should be stable",
                    "criterion": "seizure disorder stability",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "should have not experienced a significant increase in seizure frequency within 2 weeks prior to enrollment",
                    "criterion": "seizure frequency",
                    "requirements": [
                        {
                            "requirement_type": "change in frequency",
                            "expected_value": "no significant increase"
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks prior to enrollment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients 2-17 years of age must have a blood pressure that is =< 95th percentile for age, height, and sex at the time of enrollment. Patients >= 18 years of age must have a blood pressure =< 130/80 mmHg at the time of enrollment (with or without the use of antihypertensive medications).",
            "criterions": [
                {
                    "exact_snippets": "Patients 2-17 years of age ... blood pressure that is =< 95th percentile for age, height, and sex at the time of enrollment",
                    "criterion": "blood pressure (patients 2-17 years)",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 17,
                                        "unit": "years"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "blood pressure percentile",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 95,
                                        "unit": "percentile"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "reference population",
                            "expected_value": [
                                "age",
                                "height",
                                "sex"
                            ]
                        },
                        {
                            "requirement_type": "timepoint",
                            "expected_value": "at the time of enrollment"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients >= 18 years of age ... blood pressure =< 130/80 mmHg at the time of enrollment (with or without the use of antihypertensive medications)",
                    "criterion": "blood pressure (patients >= 18 years)",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 18,
                                        "unit": "years"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "blood pressure",
                            "expected_value": {
                                "operator": "<=",
                                "value": 130,
                                "unit": "mmHg systolic / 80 mmHg diastolic"
                            }
                        },
                        {
                            "requirement_type": "timepoint",
                            "expected_value": "at the time of enrollment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have neurofibromatosis type 1 (NF1) based on clinical criteria and/or germline genetic testing",
            "criterions": [
                {
                    "exact_snippets": "neurofibromatosis type 1 (NF1) based on clinical criteria and/or germline genetic testing",
                    "criterion": "neurofibromatosis type 1 (NF1) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis_method",
                            "expected_value": [
                                "clinical criteria",
                                "germline genetic testing"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Corrected QT (QTc) interval =< 450 msec by electrocardiography (EKG) (within 4 weeks prior to enrollment)",
            "criterions": [
                {
                    "exact_snippets": "Corrected QT (QTc) interval =< 450 msec by electrocardiography (EKG)",
                    "criterion": "corrected QT (QTc) interval",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 450,
                                "unit": "msec"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For all patients, an MRI of the brain (with orbital cuts for optic pathway tumors) and/or spine (depending on the site(s) of primary disease) with and without contrast must be performed within 8 weeks prior to enrollment",
            "criterions": [
                {
                    "exact_snippets": "an MRI of the brain ... must be performed within 8 weeks prior to enrollment",
                    "criterion": "MRI of the brain",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 8,
                                "unit": "weeks prior to enrollment"
                            }
                        },
                        {
                            "requirement_type": "contrast",
                            "expected_value": [
                                "with",
                                "without"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "orbital cuts for optic pathway tumors",
                    "criterion": "orbital cuts in brain MRI",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "indication",
                            "expected_value": "if optic pathway tumors"
                        }
                    ]
                },
                {
                    "exact_snippets": "MRI of the ... spine (depending on the site(s) of primary disease) ... must be performed within 8 weeks prior to enrollment",
                    "criterion": "MRI of the spine",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 8,
                                "unit": "weeks prior to enrollment"
                            }
                        },
                        {
                            "requirement_type": "indication",
                            "expected_value": "depending on the site(s) of primary disease"
                        },
                        {
                            "requirement_type": "contrast",
                            "expected_value": [
                                "with",
                                "without"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have a body surface area (BSA) of >= 0.5 m^2 at enrollment",
            "criterions": [
                {
                    "exact_snippets": "body surface area (BSA) of >= 0.5 m^2 at enrollment",
                    "criterion": "body surface area (BSA)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.5,
                                "unit": "m^2"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with metastatic disease or multiple independent primary LGGs are allowed on study",
            "criterions": [
                {
                    "exact_snippets": "Patients with metastatic disease ... are allowed on study",
                    "criterion": "metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "multiple independent primary LGGs are allowed on study",
                    "criterion": "multiple independent primary LGGs",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin =< 1.5 x upper limit of normal (ULN) for age (within 7 days prior to enrollment) (children with a diagnosis of Gilbert's syndrome will be allowed on study regardless of their total and indirect [unconjugated] bilirubin levels as long as their direct [conjugated] bilirubin is < 3.1 mg/dL)",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin =< 1.5 x upper limit of normal (ULN) for age (within 7 days prior to enrollment)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN for age"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "children with a diagnosis of Gilbert's syndrome will be allowed on study regardless of their total and indirect [unconjugated] bilirubin levels as long as their direct [conjugated] bilirubin is < 3.1 mg/dL",
                    "criterion": "direct (conjugated) bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3.1,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "children with a diagnosis of Gilbert's syndrome",
                    "criterion": "Gilbert's syndrome diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* All patients must have ophthalmology toxicity assessments performed within 8 weeks prior to enrollment",
            "criterions": [
                {
                    "exact_snippets": "ophthalmology toxicity assessments performed within 8 weeks prior to enrollment",
                    "criterion": "ophthalmology toxicity assessment",
                    "requirements": [
                        {
                            "requirement_type": "performed_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 8,
                                "unit": "weeks prior to enrollment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Although not required, if a biopsy/tumor resection is performed, eligible histologies will include all tumors considered LGG or low-grade astrocytoma (World Health Organization [WHO] grade I and II) by 5th edition WHO classification of central nervous system (CNS) tumors with the exception of subependymal giant cell astrocytoma",
            "criterions": [
                {
                    "exact_snippets": "eligible histologies will include all tumors considered LGG or low-grade astrocytoma (World Health Organization [WHO] grade I and II) by 5th edition WHO classification of central nervous system (CNS) tumors",
                    "criterion": "tumor histology",
                    "requirements": [
                        {
                            "requirement_type": "histology type",
                            "expected_value": [
                                "LGG",
                                "low-grade astrocytoma"
                            ]
                        },
                        {
                            "requirement_type": "WHO grade",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "with the exception of subependymal giant cell astrocytoma",
                    "criterion": "tumor histology",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": "subependymal giant cell astrocytoma"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Surgery within 2 weeks prior to enrollment, with the exception of surgical placement for vascular access or cerebrospinal fluid (CSF) diverting procedures such as endoscopic third ventriculostomy (ETV) and ventriculo-peritoneal (VP) shunt.",
            "criterions": [
                {
                    "exact_snippets": "Surgery within 2 weeks prior to enrollment, with the exception of surgical placement for vascular access or cerebrospinal fluid (CSF) diverting procedures such as endoscopic third ventriculostomy (ETV) and ventriculo-peritoneal (VP) shunt.",
                    "criterion": "recent surgery",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks prior to enrollment"
                            }
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": "not vascular access or CSF diverting procedures (ETV, VP shunt)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Severe valvular heart disease",
            "criterions": [
                {
                    "exact_snippets": "Severe valvular heart disease",
                    "criterion": "valvular heart disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Symptomatic heart failure",
            "criterions": [
                {
                    "exact_snippets": "Symptomatic heart failure",
                    "criterion": "heart failure",
                    "requirements": [
                        {
                            "requirement_type": "symptom presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have an uncontrolled infection are not eligible",
            "criterions": [
                {
                    "exact_snippets": "uncontrolled infection",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "controlled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known genetic disorder that increases risk for coronary artery disease. Note: The presence of dyslipidemia in a family with a history of myocardial infarction is not in itself an exclusion unless there is a known genetic disorder documented",
            "criterions": [
                {
                    "exact_snippets": "Known genetic disorder that increases risk for coronary artery disease",
                    "criterion": "genetic disorder increasing coronary artery disease risk",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "risk_increase_for",
                            "expected_value": "coronary artery disease"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cardiac conditions:",
            "criterions": [
                {
                    "exact_snippets": "Cardiac conditions",
                    "criterion": "cardiac conditions",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with any serious medical or psychiatric illness/ condition, including substance use disorders likely in the judgement of the investigator to interfere or limit compliance with study requirements/treatment are not eligible",
            "criterions": [
                {
                    "exact_snippets": "any serious medical or psychiatric illness/ condition, including substance use disorders",
                    "criterion": "serious medical or psychiatric illness/condition, including substance use disorders",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Supplementation with vitamin E greater than 100% of the daily recommended dose. Any multivitamin containing vitamin E must be stopped prior to study enrollment even if less than 100% of the daily recommended dosing for vitamin E",
            "criterions": [
                {
                    "exact_snippets": "Supplementation with vitamin E greater than 100% of the daily recommended dose",
                    "criterion": "vitamin E supplementation",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 100,
                                "unit": "% of daily recommended dose"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Any multivitamin containing vitamin E must be stopped prior to study enrollment even if less than 100% of the daily recommended dosing for vitamin E",
                    "criterion": "multivitamin containing vitamin E",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* New York Heart Association (NYHA) class II-IV prior or current cardiomyopathy",
            "criterions": [
                {
                    "exact_snippets": "New York Heart Association (NYHA) class II-IV",
                    "criterion": "New York Heart Association (NYHA) class",
                    "requirements": [
                        {
                            "requirement_type": "class",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "prior or current cardiomyopathy",
                    "criterion": "cardiomyopathy",
                    "requirements": [
                        {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must not have received any prior tumor-directed therapy including chemotherapy, radiation therapy, immunotherapy, or bone marrow transplant. Prior surgical intervention is permitted",
            "criterions": [
                {
                    "exact_snippets": "must not have received any prior tumor-directed therapy including chemotherapy, radiation therapy, immunotherapy, or bone marrow transplant",
                    "criterion": "prior tumor-directed therapy",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior surgical intervention is permitted",
                    "criterion": "prior surgical intervention",
                    "requirements": [
                        {
                            "requirement_type": "history of surgical intervention",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current or past history of retinal vein occlusion or retinal detachment",
            "criterions": [
                {
                    "exact_snippets": "Current or past history of retinal vein occlusion",
                    "criterion": "retinal vein occlusion",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Current or past history of ... retinal detachment",
                    "criterion": "retinal detachment",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Note: Patients must have healed from any prior surgery prior to enrollment",
            "criterions": [
                {
                    "exact_snippets": "Patients must have healed from any prior surgery prior to enrollment",
                    "criterion": "healing from prior surgery",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "healed"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Lactating females who plan to breastfeed their infants are not eligible",
            "criterions": [
                {
                    "exact_snippets": "Lactating females",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "lactating",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "plan to breastfeed their infants",
                    "criterion": "breastfeeding intention",
                    "requirements": [
                        {
                            "requirement_type": "intention to breastfeed",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who, in the opinion of the investigator, are not able to comply with the study procedures are not eligible",
            "criterions": [
                {
                    "exact_snippets": "Patients who, in the opinion of the investigator, are not able to comply with the study procedures",
                    "criterion": "ability to comply with study procedures",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation and for 12 weeks after stopping study therapy are not eligible",
            "criterions": [
                {
                    "exact_snippets": "Sexually active patients of reproductive potential",
                    "criterion": "reproductive potential and sexual activity",
                    "requirements": [
                        {
                            "requirement_type": "reproductive potential",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "sexual activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "have not agreed to use an effective contraceptive method for the duration of their study participation and for 12 weeks after stopping study therapy",
                    "criterion": "contraceptive method use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use effective contraceptive method",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration of contraceptive use",
                            "expected_value": [
                                "for the duration of their study participation",
                                "for 12 weeks after stopping study therapy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with uncontrolled glaucoma",
            "criterions": [
                {
                    "exact_snippets": "uncontrolled glaucoma",
                    "criterion": "glaucoma",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of atrial fibrillation",
            "criterions": [
                {
                    "exact_snippets": "History of atrial fibrillation",
                    "criterion": "atrial fibrillation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ophthalmologic conditions:",
            "criterions": [
                {
                    "exact_snippets": "Ophthalmologic conditions",
                    "criterion": "ophthalmologic conditions",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If checking pressure is clinically indicated, patients with intraocular pressure (IOP) > 22 mmHg or ULN adjusted by age are not eligible",
            "criterions": [
                {
                    "exact_snippets": "patients with intraocular pressure (IOP) > 22 mmHg or ULN adjusted by age are not eligible",
                    "criterion": "intraocular pressure (IOP)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 22,
                                        "unit": "mmHg"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "ULN adjusted by age"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current or past history of central serous retinopathy",
            "criterions": [
                {
                    "exact_snippets": "Current or past history of central serous retinopathy",
                    "criterion": "central serous retinopathy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients may not be receiving any other investigational agents",
            "criterions": [
                {
                    "exact_snippets": "may not be receiving any other investigational agents",
                    "criterion": "receipt of other investigational agents",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatments and/or medications patient is receiving that would make her/him ineligible, such as:",
            "criterions": [
                {
                    "exact_snippets": "Treatments and/or medications patient is receiving that would make her/him ineligible",
                    "criterion": "current treatments and/or medications",
                    "requirements": [
                        {
                            "requirement_type": "eligibility impact",
                            "expected_value": "would make patient ineligible"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female patients who are pregnant are not eligible since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential",
            "criterions": [
                {
                    "exact_snippets": "Female patients who are pregnant are not eligible",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnancy",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "A pregnancy test is required for female patients of childbearing potential",
                    "criterion": "pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "applicability",
                            "expected_value": "female patients of childbearing potential"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Note: Women of child-bearing potential and males with sexual partners who are pregnant or who could become pregnant (i.e., women of child-bearing potential) should use effective methods of contraception for the duration of the study and for 12 weeks after stopping study therapy to avoid pregnancy and/or potential adverse effects on the developing embryo",
            "criterions": [
                {
                    "exact_snippets": "Women of child-bearing potential ... should use effective methods of contraception for the duration of the study and for 12 weeks after stopping study therapy",
                    "criterion": "contraception use (women of child-bearing potential)",
                    "requirements": [
                        {
                            "requirement_type": "use of effective contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "for the duration of the study and for 12 weeks after stopping study therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "males with sexual partners who are pregnant or who could become pregnant (i.e., women of child-bearing potential) should use effective methods of contraception for the duration of the study and for 12 weeks after stopping study therapy",
                    "criterion": "contraception use (males with partners who are or could become pregnant)",
                    "requirements": [
                        {
                            "requirement_type": "use of effective contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "for the duration of the study and for 12 weeks after stopping study therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with a concurrent malignancy or history of treatment (other than surgery) for another tumor within the last year are ineligible",
            "criterions": [
                {
                    "exact_snippets": "Patients with a concurrent malignancy ... are ineligible",
                    "criterion": "concurrent malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "history of treatment (other than surgery) for another tumor within the last year are ineligible",
                    "criterion": "treatment for another tumor within the last year (excluding surgery)",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment type",
                            "expected_value": {
                                "operator": "!=",
                                "value": 1,
                                "unit": "surgery"
                            }
                        },
                        {
                            "requirement_type": "time since treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ophthalmological findings secondary to long-standing optic pathway glioma (such as visual loss, optic nerve pallor, or strabismus) or longstanding orbito-temporal plexiform neurofibroma (PN), such as visual loss, strabismus) will NOT be considered a significant abnormality for the purposes of the study",
            "criterions": [
                {
                    "exact_snippets": "Ophthalmological findings secondary to long-standing optic pathway glioma (such as visual loss, optic nerve pallor, or strabismus)",
                    "criterion": "ophthalmological findings secondary to long-standing optic pathway glioma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "longstanding orbito-temporal plexiform neurofibroma (PN), such as visual loss, strabismus",
                    "criterion": "ophthalmological findings secondary to longstanding orbito-temporal plexiform neurofibroma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* Platelets >= 100,000/uL (unsupported) (within 7 days prior to enrollment)",
            "criterions": [
                {
                    "exact_snippets": "Platelets >= 100,000/uL (within 7 days prior to enrollment)",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "uL"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 7 days prior to enrollment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count >= 1,000/uL (unsupported) (within 7 days prior to enrollment)",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count >= 1,000/uL (within 7 days prior to enrollment)",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "uL"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 7 days prior to enrollment"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}